Actinium Pharmaceuticals, Inc. (ATNM) Earnings History
Net Loss20 years of earnings data (2006–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Actinium Pharmaceuticals, Inc. (ATNM) Earnings Overview
As of June 22, 2026, Actinium Pharmaceuticals, Inc. (ATNM) reported trailing twelve-month net income of -$23M, reflecting +14.2% year-over-year growth. The company earned $-0.75 per diluted share over the past four quarters, with a net profit margin of -37652.2%.
Looking at the long-term picture, ATNM's historical earnings data spans multiple years. The company achieved its highest annual net income of $10,289 in fiscal 2011.
Actinium Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RNAC (-$152M net income, -4658.6% margin), RAIN (-$9M net income), PHAT (-$127M net income, -126.3% margin), ATNM has room to improve margins relative to the peer group. Compare ATNM vs RNAC →
ATNM Earnings vs Peers
Earnings metrics vs comparable public companies
ATNM Historical Earnings Data (2006–2025)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$34M | +11.4% | -$36M | $-1.09 | -37652.2% | -40274.4% |
| 2024 | -$38M | +21.7% | -$42M | $-1.27 | - | - |
| 2023 | -$49M | -47.9% | -$52M | $-1.83 | -60269.1% | -64098.8% |
| 2022 | -$33M | -33.3% | -$34M | $-1.37 | -3205.5% | -3311.1% |
| 2021 | -$25M | -11.5% | -$25M | $-1.20 | -2165.6% | -2182.2% |
| 2020 | -$22M | -1.4% | -$22M | $-1.83 | - | - |
| 2019 | -$22M | +7.4% | -$22M | $-4.37 | - | - |
| 2018 | -$24M | +11.1% | -$24M | $-6.69 | - | - |
| 2017 | -$27M | -9.4% | -$27M | $-11.96 | - | - |
| 2016 | -$24M | -15.7% | -$27M | $-15.06 | - | - |
| 2015 | -$21M | +14.8% | -$25M | $-16.53 | - | - |
| 2014 | -$25M | -129.1% | -$22M | $-27.07 | - | - |
| 2013 | -$11M | -28.9% | -$7M | $-14.21 | - | - |
| 2012 | -$8M | -81361.5% | -$8M | $-227.31 | - | - |
| 2011 | $10,289 | +514.6% | $-9,952 | $0.38 | - | - |
| 2010 | $1,674 | +107.5% | $-26,053 | $0.00 | - | - |
| 2009 | $-22,331 | +28.5% | $-16,025 | $-0.06 | - | - |
| 2008 | $-31,243 | -111.1% | $-26,419 | $-0.08 | - | - |
| 2007 | $-14,800 | +19.6% | $-11,993 | $-0.04 | - | - |
| 2006 | $-18,404 | - | $-17,534 | $-0.24 | - | - |
Download Data
Export ATNM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ATNM — Frequently Asked Questions
Quick answers to the most common questions about buying ATNM stock.
What is ATNM earnings per share (EPS)?
ATNM trailing twelve-month (TTM) diluted EPS is $-0.75, reflecting +14.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2006 to 2025 is available in the table on this page.
What is Actinium Pharmaceuticals, Inc.'s net income?
Actinium Pharmaceuticals, Inc. (ATNM) trailing twelve-month net income is $-23M as of 2025. Earnings grew +14.2% year-over-year.
Is ATNM profitable?
ATNM is not currently profitable on a TTM basis, reporting a net loss of $-23M. Net margin is -37652.2%. Investors should monitor for a return to profitability.
What is ATNM's earnings growth rate?
ATNM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2006 to 2025.
What are ATNM's profit margins?
Actinium Pharmaceuticals, Inc. net profit margin is -37652.2%, operating margin is -40274.4%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -167.0%.
Is ATNM growing earnings?
ATNM is growing earnings steadily. YoY EPS growth of +14.2% is consistent with the 5-year CAGR of N/A. TTM net income is $-23M.
What was ATNM's best earnings year?
Actinium Pharmaceuticals, Inc.'s highest annual net income on record is $10289.00, achieved in fiscal year 2011. Earnings history on this page spans 2006 to 2025 and includes all annual and quarterly figures.
What were ATNM's earnings last quarter?
ATNM's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-0.18. For a full breakdown of all quarters, see the quarterly earnings table on this page.